Key facts today
Vertex Pharmaceuticals' stock dropped 14% in premarket and 17.8% to $388.43 after halting its painkiller VX-993 due to failure in a mid-stage trial despite showing some pain reduction.
Vertex Pharmaceuticals reported that its next-generation oral pain drug failed to meet the primary endpoint in a mid-stage clinical trial.
Vertex Pharmaceuticals saw strong revenue growth in Q2 2025, fueled by successful product launches CASGEVY, ALYFTREK, and JOURNAVX, while advancing its cystic fibrosis pipeline.
−0.00 BRL
−2.89 B BRL
59.22 B BRL
About Vertex Pharmaceuticals Incorporated
Sector
Industry
CEO
Reshma Kewalramani
Website
Headquarters
Boston
Founded
1989
ISIN
BRVRTXBDR001
FIGI
BBG00P14KF71
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Related stocks
VRTX Tight Triangle Breakout – Watch Closely
🧠 Chart Analysis Summary:
Pattern: A symmetrical triangle is visible, tightening toward the apex with a breakout just forming.
Current Price: $472.47 (breakout near)
Key Levels:
Support Zone: Around $468–470 (white/yellow zone)
Resistance Zone:
First Target: $477.01 (red line)
Major Target:
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH
(1/9)
Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀
(2/9) – REVENUE RUSH
• Q4 Haul: $ 2.91B—16% jump from l
Vertex Pharmaceuticals Pulls Back After RallyVertex Pharmaceuticals ended January with a big rally. Now, after a pullback, some traders may see an opportunity.
The first pattern on today’s chart is the price gap on January 31 after the FDA approved its Journavx painkiller. (It’s the first of its kind to treat pain in a unique way without addi
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associ
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where VRTX34 is featured.